TriVascular, Inc.
TriVascular, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at TriVascular, Inc..
TriVascular, Inc. is a company.
Key people at TriVascular, Inc..
Key people at TriVascular, Inc..
TriVascular Technologies, Inc. (NASDAQ: TRIV) was a medical device company that developed endovascular repair devices, specifically novel grafts, for the minimally invasive treatment of abdominal aortic aneurysms (AAA).[1][2][3] It served vascular surgeons and patients with AAA, a serious condition where the abdominal aorta weakens and bulges, risking rupture, by advancing endovascular aortic repair (EVAR) technologies to improve outcomes over traditional open surgery.[1][2] Founded in 1998 and headquartered in Santa Rosa, California, the company raised $220.67M before being acquired by Endologix in February 2016 for a $211M enterprise valuation, marking the end of its independent operations.[1][2]
TriVascular was established in 1998 in Santa Rosa, California, with a focus on pioneering design and manufacturing technologies for EVAR solutions.[1][2] Specific founders are not detailed in available records, but the company emerged amid growing demand for minimally invasive vascular treatments, building on innovations in stent grafts to address limitations in existing AAA repair methods.[1][3] Early traction included securing significant funding—totaling over $220M across rounds—and advancing products through development, culminating in its public listing and eventual acquisition by Endologix in 2016, a pivotal moment that integrated its technologies into a larger vascular disease platform.[1][2]
TriVascular rode the wave of minimally invasive medical devices in the vascular health sector, capitalizing on trends toward endovascular procedures that lowered patient risks and recovery times for AAA, a condition affecting millions globally.[1][3] Timing was ideal in the 2000s-2010s, as aging populations drove demand for AAA treatments amid advances in stent graft durability and deployment precision.[1] Market forces like regulatory approvals for EVAR and competition from firms like Endologix favored innovators, positioning TriVascular to influence the ecosystem through tech integration post-acquisition, enhancing Endologix's portfolio and contributing to broader adoption of less invasive vascular interventions.[1][2]
Post-2016 acquisition, TriVascular operates as part of Endologix, with its EVAR technologies likely integrated into ongoing AAA treatments rather than as a standalone entity.[1] Future shape comes from enduring trends in vascular medtech—AI-enhanced imaging, bioresorbable materials, and expanded indications for aneurysms—which could evolve its legacy through Endologix's innovations.[1] Its influence may grow indirectly via improved procedural standards, underscoring how specialized grafts like TriVascular's advanced minimally invasive AAA care from niche to standard.
